HADI ESTAKHRI: Open Payments
NPI 1003161522 · NEWPORT BEACH, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,306 in 225 payments from 24 companies in 2025. Trend: 2023 $4,120 · 2024 $4,047 · 2025 $5,306
Food & beverage: $5,306
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 40 | $1,020 |
| Neurocrine BioSciences, Inc. | 19 | $588 |
| Vanda Pharmaceuticals Inc. | 15 | $501 |
| Janssen Pharmaceuticals, Inc | 11 | $431 |
| Otsuka America Pharmaceutical, Inc. | 16 | $344 |
| Alkermes, Inc. | 17 | $336 |
| Lundbeck LLC | 16 | $294 |
| ABBVIE INC. | 17 | $289 |
| Teva Pharmaceuticals USA, Inc. | 14 | $247 |
| Supernus Pharmaceuticals, Inc. | 11 | $242 |
Products named: CAPLYTA, INGREZZA, SPRAVATO, REXULTI, HETLIOZ, ARISTADA, VRAYLAR, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
